Clinical Trial Update: Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant study (ROSALINE) investigates targeting ROS1 in combination with endocrine therapy for invasive lobular carcinoma of the breast; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Lobular Carcinoma of the Breast

Drugs mentioned

• ROS1 inhibitor (ROSALINE trial)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING